GlassScriptPhysician profile
Jessica Whitlock
NPI 1295107506
$4,936.58
in general payments reported to CMS, 2019-2025
24 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $898 · 2023: $819 · 2024: $1,518 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,754.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $750.41 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Lilly USA, LLC | $426.10 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $337.65 | 2022-2025 | Arexvy, Shingrix, Boostrix |
| Novo Nordisk INC | $265.84 | 2021-2025 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $244.42 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Genzyme Corporation | $227.00 | 2024-2025 | |
| Corcept Therapeutics | $206.90 | 2025 | Korlym |
| Amgen INC. | $186.80 | 2023-2024 | Evenity |
| Mallinckrodt Hospital Products INC. | $129.51 | 2023 | Terlivaz |
| Axsome Therapeutics, INC. | $124.99 | 2025 | Auvelity |
| Kyowa Kirin, INC. | $121.83 | 2023 | Nourianz |
| Sk Life Science, INC. | $111.17 | 2022 | |
| Abbott Laboratories | $110.60 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $102.80 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $101.45 | 2023 | Flexitouch Plus, Entre Plus |
| Abiomed | $95.47 | 2024 | Impella |
| Vertos Medical, INC. | $94.28 | 2024 | Mild Device Kit |
| Boston Scientific Corporation | $86.74 | 2025 | Watchman Access System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.38 | 2025 | |
| Tris Pharma INC | $83.19 | 2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Pfizer INC. | $80.95 | 2023-2025 | |
| Amphastar Pharmaceuticals, INC. | $14.85 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Whitlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.